Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FALMINA vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Bulimia nervosa,Premenstrual dysphoric disorder
Prevention of pregnancy
FALMINA (fictitious drug): 500 mg orally every 12 hours.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life 12-15 hours; in severe renal impairment (Cr Cl <30 m L/min) extends to 30-40 hours, requiring dose adjustment.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Hepatic via CYP2D6; active metabolite norfluoxetine; elimination half-life 4-6 days (fluoxetine), 4-16 days (norfluoxetine).
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
98% bound to albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.2-0.3 L/kg, reflecting confinement to plasma and interstitial space; minimal tissue penetration.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 75-85% due to moderate first-pass metabolism; IV: 100%.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
GFR 30-59 m L/min: 500 mg every 24 hours. GFR 15-29 m L/min: 250 mg every 24 hours. GFR <15 m L/min: 125 mg every 24 hours. Hemodialysis: 125 mg post-dialysis.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: use with caution; 250 mg every 24 hours.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
5 mg/kg/dose orally every 12 hours; maximum 500 mg/dose.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Initiate at 250 mg orally every 12 hours; titrate to renal function.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Serotonin syndrome; discontinuation syndrome; hyponatremia; bleeding risk; mania/hypomania; seizures; angle-closure glaucoma; QT prolongation (overdose).
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Concurrent use with MAOIs or within 14 days of MAOI use; concurrent use with pimozide or thioridazine; hypersensitivity to fluoxetine.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid high-sodium foods as they can counteract the diuretic effect. Limit licorice intake (glycyrrhizin) which can worsen hypokalemia. Grapefruit juice may increase absorption; avoid large amounts. Maintain adequate fluid intake unless fluid restriction is advised.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malformations in exposed fetuses based on epidemiological studies, but use is not recommended due to lack of need. Second and third trimesters: associated with increased risk of fetal harm including congenital anomalies (limb defects, heart defects) and adverse outcomes (low birth weight, preterm birth) from continued exposure. Risk of fetal feminization from progestin component in late pregnancy.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of ethinylestradiol and drospirenone are excreted in breast milk; M/P ratio not determined. Use may reduce milk production and composition. Avoid use in breastfeeding women, especially during early postpartum period, due to potential for decreased milk supply and presence in milk. Alternative contraception recommended.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Falmina is contraindicated in pregnancy; no dose adjustments are applicable because use should be discontinued immediately upon pregnancy diagnosis. No pharmacokinetic data guide dosing in pregnancy as it is not indicated.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
FALMINA is a high-ceiling loop diuretic used for edema and hypertension. Monitor serum potassium and magnesium regularly; risk of hypokalemia and hypomagnesemia. Ototoxicity is dose-dependent and more common with rapid IV administration or concurrent use of other ototoxic drugs. Onset of action: oral 30-60 min, IV 5 min. Duration: oral 6-8 hr, IV 2 hr. Avoid in anuria, hepatic coma, severe electrolyte depletion.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take this medication exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any hearing loss, ringing in ears, or dizziness immediately, especially if on high doses or other ototoxic drugs.,Weigh yourself daily and notify your doctor if you gain more than 2-3 pounds in 24 hours or lose weight too quickly.,Avoid sudden position changes to prevent dizziness; rise slowly from sitting or lying down.,Limit alcohol intake as it may worsen dizziness and low blood pressure.,This drug may increase blood sugar; monitor glucose if diabetic.,Do not take with NSAIDs (e.g., ibuprofen, aspirin) unless approved by your doctor as they may reduce effectiveness and increase kidney risk.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FALMINA vs ALYACEN 1/35, answered by our medical review team.
FALMINA is a Oral Contraceptive that works by Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FALMINA and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FALMINA is: FALMINA (fictitious drug): 500 mg orally every 12 hours.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FALMINA and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FALMINA is classified as Category C. Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malform. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.